Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07211126) titled 'The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France' on Sept. 29.
Study Type: Observational
Primary Sponsor: Tandem Diabetes Care, Inc.
Condition:
Diabetes Mellitus, Type 1
Intervention:
Device: t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)
Recruitment Status: Not recruiting
Date of First Enrollment: December 2025
Target Sample Size: 350
To know more, visit https://clinicaltrials.gov/study/NCT07211126
Disclaimer: Curated by HT Syndication....